Home » Stocks » SNDX

Syndax Pharmaceuticals, Inc. (SNDX)

Stock Price: $18.11 USD 0.19 (1.06%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $17.30 -0.81 (-4.47%) May 13, 5:39 PM
Market Cap 844.13M
Revenue (ttm) 1.52M
Net Income (ttm) -89.55M
Shares Out 51.50M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $18.11
Previous Close $17.92
Change ($) 0.19
Change (%) 1.06%
Day's Open 17.85
Day's Range 16.87 - 18.54
Day's Volume 702,426
52-Week Range 13.02 - 27.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2 AUGMENT-101 trial evaluating SNDX-5613 in patient...

1 day ago - Benzinga

Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 3.57% year over year to ($0.54), which bea...

2 days ago - Benzinga

WALTHAM, Mass., May 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...

2 days ago - PRNewsWire

WALTHAM, Mass., May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of...

1 week ago - PRNewsWire

Syndax (SNDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 weeks ago - Zacks Investment Research

The company announced results from an early-stage clinical study.

3 weeks ago - The Motley Fool

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Ri...

Other stocks mentioned: KALV, CRSP
3 weeks ago - Benzinga

WALTHAM, Mass., April 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

3 weeks ago - PRNewsWire

WALTHAM, Mass., April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

4 weeks ago - PRNewsWire

The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.

1 month ago - Zacks Investment Research

WALTHAM, Mass., April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

1 month ago - PRNewsWire

The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.

1 month ago - Zacks Investment Research

WALTHAM, Mass., March 31, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline...

1 month ago - PRNewsWire

Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.44), wh...

2 months ago - Benzinga

WALTHAM, Mass., March 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

2 months ago - PRNewsWire

WALTHAM, Mass., Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

4 months ago - PRNewsWire

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody for GVHD.

4 months ago - Seeking Alpha

WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...

5 months ago - PRNewsWire

WALTHAM, Mass., Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...

5 months ago - PRNewsWire

Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

WALTHAM, Mass., Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...

5 months ago - PRNewsWire

WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

5 months ago - PRNewsWire

WALTHAM, Mass., Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

6 months ago - PRNewsWire

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

WALTHAM, Mass., Aug. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc.

9 months ago - PRNewsWire

Syndax's Latest Data Disappoints, But The True Value Lies With SNDX-5613 And SNDX-6352

11 months ago - Seeking Alpha

Syndax Pharmaceuticals stock tumbled to a month-low Friday after the biotech's breast cancer treatment failed in a Phase 3 test. Syndax says it won't be asking for FDA approval.

11 months ago - Investors Business Daily

WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer ...

11 months ago - PRNewsWire

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Initial data from an early-stage leukemia trial is promising.

1 year ago - The Motley Fool

Shares of Syndax Pharmaceuticals soared to a record high Tuesday after the biotech company unveiled promising results for its early-stage blood cancer treatment in leukemia patients. The post Why This ...

1 year ago - Investors Business Daily

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.

1 year ago - Zacks Investment Research

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).

1 year ago - Zacks Investment Research

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April.

Other stocks mentioned: APLS, MDCO
1 year ago - 24/7 Wall Street

Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

As stocks keep pushing to highs again and again, where can you find smart stocks to buy right now? Check out these 7 excellent options.

Other stocks mentioned: MS, NFLX, OGI, QURE, REAL, SFIX
1 year ago - InvestorPlace

Syndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 3, 2016
CEO
Arlene Morris
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
SNDX
Full Company Profile

Financial Performance

In 2020, SNDX's revenue was $1.52 million, a change of 0.00% compared to the previous year's $1.52 million. Losses were -$77.06 million, 37.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is 28.60, which is an increase of 57.92% from the latest price.

Price Target
$28.60
(57.92% upside)
Analyst Consensus: Strong Buy